D89 Stock Overview
A biotechnology company, focuses on the discovery, development, and commercialization of anti infectives in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Destiny Pharma plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.093 |
| 52 Week High | UK£0.93 |
| 52 Week Low | UK£0.089 |
| Beta | 0.28 |
| 11 Month Change | -48.04% |
| 3 Month Change | -67.71% |
| 1 Year Change | -66.79% |
| 33 Year Change | -94.08% |
| 5 Year Change | n/a |
| Change since IPO | -91.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| D89 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -16.2% | -1.8% | -0.1% |
| 1Y | -66.8% | -18.5% | 2.4% |
Return vs Industry: D89 underperformed the German Biotechs industry which returned -18.5% over the past year.
Return vs Market: D89 underperformed the German Market which returned 2.4% over the past year.
Price Volatility
| D89 volatility | |
|---|---|
| D89 Average Weekly Movement | 16.0% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: D89's share price has been volatile over the past 3 months.
Volatility Over Time: D89's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 15 | Chris Tovey | www.destinypharma.com |
Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of anti infectives in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria. It also develops XF Drugs Research/Biofilms that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections.
Destiny Pharma plc Fundamentals Summary
| D89 fundamental statistics | |
|---|---|
| Market cap | €9.61m |
| Earnings (TTM) | -€6.68m |
| Revenue (TTM) | €981.82k |
10.0x
P/S Ratio-1.5x
P/E RatioIs D89 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| D89 income statement (TTM) | |
|---|---|
| Revenue | UK£831.55k |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£831.55k |
| Other Expenses | UK£6.49m |
| Earnings | -UK£5.66m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.059 |
| Gross Margin | 100.00% |
| Net Profit Margin | -680.30% |
| Debt/Equity Ratio | 0% |
How did D89 perform over the long term?
See historical performance and comparison